作者: Jian Li , Craig R Rayner , Roger Leigh Nation , R Deans , Robert Boots
DOI: 10.1128/AAC.49.11.4814-4815.2005
关键词:
摘要: Intravenous colistin methanesulfonate (CMS) is increasingly the last line of defense for multidrug-resistant gram-negative bacteria and now being used as “salvage” therapy in critically ill patients ([1][1], [7][2], [9][3], [11][4]). CMS converted vivo to colistin, these two